iDenfy’s revamped AML Screening software now includes new risk categories, better PEP status labeling, and other built-in AML features Delaware, United States, October 29, 2025-- iDenfy, a global ...

Beyond Analysis has launched a new sister company Beyond AML which will assist financial institutions to leverage applied intelligence, data analytics and machine learning to optimise their end-to-end ...

CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...